Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 1973834, 18 pages
http://dx.doi.org/10.1155/2016/1973834
Review Article

New Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple Sclerosis

Department of Neurology in Zabrze, Medical University of Silesia, ul. 3 Maja 13-15, 41-800 Zabrze, Poland

Received 18 May 2016; Revised 5 August 2016; Accepted 19 September 2016

Academic Editor: Capucine Trollet

Copyright © 2016 Bożena Adamczyk and Monika Adamczyk-Sowa. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Fiorini, T. Koudriavtseva, E. Bucaj et al., “Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis,” PLoS ONE, vol. 8, no. 6, article e65184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Kalincik, “Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review,” Neuroepidemiology, vol. 44, no. 4, pp. 199–214, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Compston and A. Coles, “Multiple sclerosis,” The Lancet, vol. 372, no. 9648, pp. 1502–1517, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. B. D. Trapp, R. Ransohoff, and R. Rudick, “Axonal pathology in multiple sclerosis: relationship to neurologic disability,” Current Opinion in Neurology, vol. 12, no. 3, pp. 295–302, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. B. D. Trapp, J. Peterson, R. M. Ransohoff, R. Rudick, S. Mörk, and L. Bö, “Axonal transection in the lesions of multiple sclerosis,” The New England Journal of Medicine, vol. 338, no. 5, pp. 278–285, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. R. E. Gonsette, “Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity,” Journal of the Neurological Sciences, vol. 274, no. 1-2, pp. 48–53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Miller, A. Walczak, J. Saluk, M. B. Ponczek, and I. Majsterek, “Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis,” Clinical Biochemistry, vol. 45, no. 1-2, pp. 26–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Kohen and A. Nyska, “Oxidation of biological systems: Oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification,” Toxicologic Pathology, vol. 30, no. 6, pp. 620–650, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. McIntyre, D. F. Bohr, and A. F. Dominiczak, “Endothelial function in hypertension: the role of superoxide anion,” Hypertension, vol. 34, no. 4 I, pp. 539–545, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Genestra, “Oxyl radicals, redox-sensitive signalling cascades and antioxidants,” Cellular Signalling, vol. 19, no. 9, pp. 1807–1819, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. D. E. Koshland Jr., “The molecule of the year,” Science, vol. 258, no. 5090, p. 1861, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Friese, B. Schattling, and L. Fugger, “Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis,” Nature Reviews Neurology, vol. 10, no. 4, pp. 225–238, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Miller, “Myostimulation as an antloxldatlve factor in sclerosis multiplex,” Polski Merkuriusz Lekarski, vol. 31, no. 183, pp. 186–189, 2011. View at Google Scholar · View at Scopus
  14. J. R. Plemel, C. A. Juzwik, C. A. Benson, M. Monks, C. Harris, and M. Ploughman, “Over-the-counter anti-oxidant therapies for use in multiple sclerosis: a systematic review,” Multiple Sclerosis, vol. 21, no. 12, pp. 1485–1495, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Kees, “Dimethyl fumarate: a Janus-faced substance?” Expert Opinion on Pharmacotherapy, vol. 14, no. 11, pp. 1559–1567, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Zhang, M. Haaf, B. Todorich et al., “Cytokine toxicity to oligodendrocyte precursors is mediated by iron,” Glia, vol. 52, no. 3, pp. 199–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Halliwell, “Oxidants and human disease: some new concepts,” The FASEB Journal, vol. 1, no. 5, pp. 358–364, 1987. View at Google Scholar · View at Scopus
  18. A. Phaniendra, D. B. Jestadi, and L. Periyasamy, “Free radicals: properties, sources, targets, and their implication in various diseases,” Indian Journal of Clinical Biochemistry, vol. 30, no. 1, pp. 11–26, 2015. View at Publisher · View at Google Scholar
  19. P. Kuppusamy and J. L. Zweier, “Characterization of free radical generation by xanthine oxidase. Evidence for hydroxyl radical generation,” The Journal of Biological Chemistry, vol. 264, no. 17, pp. 9880–9884, 1989. View at Google Scholar · View at Scopus
  20. L. Haider, C. Simeonidou, G. Steinberger et al., “Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 85, no. 12, pp. 1386–1395, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. H. A. Kontos, E. P. Wei, E. F. Ellis et al., “Appearance of superoxide anion radical in cerebral extracellular space during increased prostaglandin synthesis in cats,” Circulation Research, vol. 57, no. 1, pp. 142–151, 1985. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Haider, “Inflammation, iron, energy failure, and oxidative stress in the pathogenesis of multiple sclerosis,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 725370, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Darios, N. Lambeng, J.-D. Troadec, P. P. Michel, and M. Ruberg, “Ceramide increases mitochondrial free calcium levels via caspase 8 and Bid: role in initiation of cell death,” Journal of Neurochemistry, vol. 84, no. 4, pp. 643–654, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Douki and J. Cadet, “Peroxynitrite mediated oxidation of purine bases of nucleosides and isolated DNA,” Free Radical Research, vol. 24, no. 5, pp. 369–380, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. Ľ. Kuračka, T. Kalnovičová, J. Kucharská, and P. Turčáni, “Multiple sclerosis: evaluation of purine nucleotide metabolism in central nervous system in association with serum levels of selected fat-soluble antioxidants,” Multiple Sclerosis International, vol. 2014, Article ID 759808, 9 pages, 2014. View at Publisher · View at Google Scholar
  26. H. Lassmann, J. Van Horssen, and D. Mahad, “Progressive multiple sclerosis: pathology and pathogenesis,” Nature Reviews Neurology, vol. 8, no. 11, pp. 647–656, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Dujmovic, T. Pekmezovic, R. Obrenovic et al., “Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 7, pp. 848–853, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. V. V. Bamm, D. K. Lanthier, E. L. Stephenson, G. S. T. Smith, and G. Harauz, “In vitro study of the direct effect of extracellular hemoglobin on myelin components,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1852, no. 1, pp. 92–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Halliwell, M. V. Clement, and L. H. Long, “Hydrogen peroxide in the human body,” FEBS Letters, vol. 486, no. 1, pp. 10–13, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. A. A. Starkov, “The role of mitochondria in reactive oxygen species metabolism and signaling,” Annals of the New York Academy of Sciences, vol. 1147, pp. 37–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. A. N. Carvalho, J. L. Lim, P. G. Nijland, M. E. Witte, and J. Van Horssen, “Glutathione in multiple sclerosis: more than just an antioxidant?” Multiple Sclerosis Journal, vol. 20, no. 11, pp. 1425–1431, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Sadowska-Bartosz, M. Adamczyk-Sowa, A. Gajewska, and G. Bartosz, “Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment,” Journal of Neuroimmunology, vol. 266, no. 1-2, pp. 67–74, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Bagnato, S. Hametner, B. Yao et al., “Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla,” Brain, vol. 134, no. 12, pp. 3602–3615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Rossi, C. Motta, V. Studer et al., “Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration,” Multiple Sclerosis Journal, vol. 20, no. 3, pp. 304–312, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Marballi, M. P. Quinones, F. Jimenez et al., “In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation,” Journal of Molecular Medicine, vol. 88, no. 11, pp. 1133–1141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. J. W. Hill, R. Poddar, J. F. Thompson, G. A. Rosenberg, and Y. Yang, “Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons,” Neuroscience, vol. 220, pp. 277–290, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Tronel, G. Y. Rochefort, N. Arlicot, S. Bodard, S. Chalon, and D. Antier, “Oxidative stress is related to the deleterious effects of heme oxygenase-1 in an in vivo neuroinflammatory rat model,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 264935, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Alexoudi, S. Zachaki, C. Stavropoulou et al., “Combined GSTP1 and NQO1 germline polymorphisms in the susceptibility to Multiple Sclerosis,” International Journal of Neuroscience, vol. 125, no. 1, pp. 32–37, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Falluel-Morel, N. Aubert, D. Vaudry et al., “Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells,” Journal of Neurochemistry, vol. 91, no. 5, pp. 1231–1243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Rossi, R. Furlan, V. De Chiara et al., “Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis,” Annals of Neurology, vol. 71, no. 1, pp. 76–83, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Mahad, H. Lassmann, and D. Turnbull, “Review: mitochondria and disease progression in multiple sclerosis,” Neuropathology and Applied Neurobiology, vol. 34, no. 6, pp. 577–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. C. R. N. Polachini, R. M. Spanevello, D. Zanini et al., “Evaluation of delta-aminolevulinic dehydratase activity, oxidative stress biomarkers, and vitamin D levels in patients with multiple sclerosis,” Neurotoxicity Research, vol. 29, no. 2, pp. 230–242, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Chevion, E. Berenshtein, and E. R. Stadtman, “Human studies related to protein oxidation: protein carbonyl content as a marker of damage,” Free Radical Research, vol. 33, pp. S99–S108, 2000. View at Google Scholar · View at Scopus
  44. P. G. Nijland, M. E. Witte, B. van het Hof et al., “Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: implications for multiple sclerosis,” Acta Neuropathologica Communications, vol. 2, no. 1, article 170, 2014. View at Publisher · View at Google Scholar
  45. A. Kirbas, S. Kirbas, O. Anlar, H. Efe, and A. Yilmaz, “Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis,” Journal of Clinical Neuroscience, vol. 20, no. 8, pp. 1106–1109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. M. A. Lutsky, A. M. Zemskov, and K. A. Razinkin, “[Biochemical markers of oxidative stress in different forms and phases of multiple sclerosis],” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoĭ promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe obshchestvo nevrologov [i] Vserossiĭskoe obshchestvo psikhiatrov, vol. 114, no. 11, pp. 74–77, 2014. View at Google Scholar · View at Scopus
  47. I. Tasset, C. Bahamonde, E. Agüera et al., “Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis,” Pharmacological Reports, vol. 65, no. 3, pp. 624–631, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. O. Binyamin, L. Larush, K. Frid et al., “Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant,” International Journal of Nanomedicine, vol. 10, pp. 7165–7174, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. K.-C. Wang, C.-P. Tsai, C.-L. Lee et al., “α-lipoic acid enhances endogenous peroxisome-proliferator-activated receptor-γ to ameliorate experimental autoimmune encephalomyelitis in mice,” Clinical Science, vol. 125, no. 7, pp. 329–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. S. A. Ganie, T. A. Dar, A. H. Bhat et al., “Melatonin: a potential anti-oxidant therapeutic agent for mitochondrial dysfunctions and related disorders,” Rejuvenation Research, vol. 19, no. 1, pp. 21–40, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Tenorio-Laranga, I. Peltonen, S. Keskitalo et al., “Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome,” Biochemical Pharmacology, vol. 85, no. 12, pp. 1783–1794, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. C. B. Burness and E. D. Deeks, “Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis,” CNS Drugs, vol. 28, no. 4, pp. 373–387, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Zarrouk, T. Nury, E. M. Karym et al., “Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158 N murine oligodendrocytes,” The Journal of Steroid Biochemistry and Molecular Biology, 2016. View at Publisher · View at Google Scholar
  54. P. Wang, K. Xie, C. Wang, and J. Bi, “Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis,” European Neurology, vol. 72, no. 3-4, pp. 249–254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. I. Sadowska-Bartosz, M. Adamczyk-Sowa, S. Galiniak, S. Mucha, K. Pierzchala, and G. Bartosz, “Oxidative modification of serum proteins in multiple sclerosis,” Neurochemistry International, vol. 63, no. 5, pp. 507–516, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. M. T. Fischer, R. Sharma, J. L. Lim et al., “NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury,” Brain, vol. 135, no. 3, pp. 886–899, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. V. V. Bamm and G. Harauz, “Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders?” Cellular and Molecular Life Sciences, vol. 71, no. 10, pp. 1789–1798, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Liu, Q.-C. Kan, X.-J. Zhang et al., “Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune encephalomyelitis,” Experimental and Molecular Pathology, vol. 97, no. 3, pp. 470–476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Tully and R. Shi, “New insights in the pathogenesis of multiple sclerosis-role of acrolein in neuronal and myelin damage,” International Journal of Molecular Sciences, vol. 14, no. 10, pp. 20037–20047, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Correale, “The role of microglial activation in disease progression,” Multiple Sclerosis, vol. 20, no. 10, pp. 1288–1295, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. J. S. Beckman and W. H. Koppenol, “Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly,” The American Journal of Physiology, vol. 271, no. 5, pp. C1424–C1437, 1996. View at Google Scholar · View at Scopus
  62. A. A. Mossakowski, J. Pohlan, D. Bremer et al., “Tracking CNS and systemic sources of oxidative stress during the course of chronic neuroinflammation,” Acta Neuropathologica, vol. 130, no. 6, pp. 799–814, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. O. Errea, B. Moreno, A. Gonzalez-Franquesa, P. M. Garcia-Roves, and P. Villoslada, “The disruption of mitochondrial axonal transport is an early event in neuroinflammation,” Journal of Neuroinflammation, vol. 12, article 152, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Lassmann, “Pathology and disease mechanisms in different stages of multiple sclerosis,” Journal of the Neurological Sciences, vol. 333, no. 1-2, pp. 1–4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Bros, J. M. Millward, F. Paul, R. Niesner, and C. Infante-Duarte, “Oxidative damage to mitochondria at the nodes of Ranvier precedes axon degeneration in ex vivo transected axons,” Experimental Neurology, vol. 261, pp. 127–135, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. W. Dröge, “Free radicals in the physiological control of cell function,” Physiological Reviews, vol. 82, no. 1, pp. 47–95, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Nordberg and E. S. J. Arnér, “Reactive oxygen species, antioxidants, and the mammalian thioredoxin system,” Free Radical Biology and Medicine, vol. 31, no. 11, pp. 1287–1312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  69. B. Halliwell, Free Radicals and Other Reactive Species in Disease, National University of Singapore, 2001.
  70. D. H. Mahad, B. D. Trapp, and H. Lassmann, “Pathological mechanisms in progressive multiple sclerosis,” The Lancet Neurology, vol. 14, no. 2, pp. 183–193, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Haider, M. T. Fischer, J. M. Frischer et al., “Oxidative damage in multiple sclerosis lesions,” Brain, vol. 134, no. 7, pp. 1914–1924, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. E. H. J. M. Jansen and T. Ruskovska, “Comparative analysis of serum (Anti)oxidative status para Cyrillicmeters in healthy persons,” International Journal of Molecular Sciences, vol. 14, no. 3, pp. 6106–6115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Karlík, P. Valkovič, V. Hančinová, L. Krížová, Ľ. Tóthová, and P. Celec, “Markers of oxidative stress in plasma and saliva in patients with multiple sclerosis,” Clinical Biochemistry, vol. 48, no. 1-2, pp. 24–28, 2015. View at Publisher · View at Google Scholar
  74. E. Miller, A. Walczak, I. Majsterek, and J. Kedziora, “Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course,” Journal of Neuroimmunology, vol. 257, no. 1-2, pp. 97–101, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Ljubisavljevic, I. Stojanovic, T. Cvetkovic et al., “Erythrocytes' antioxidative capacity as a potential marker of oxidative stress intensity in neuroinflammation,” Journal of the Neurological Sciences, vol. 337, no. 1-2, pp. 8–13, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. V. Chiurchiù, “Novel targets in multiple sclerosis: to oxidative stress and beyond,” Current Topics in Medicinal Chemistry, vol. 14, no. 22, pp. 2590–2599, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Sbardella, A. Greco, M. L. Stromillo et al., “Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course,” Multiple Sclerosis Journal, vol. 19, no. 4, pp. 411–417, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. O. G. Vidaurre, J. D. Haines, I. Katz Sand et al., “Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics,” Brain, vol. 137, no. 8, pp. 2271–2286, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. B. Parajuli, H. Horiuchi, T. Mizuno, H. Takeuchi, and A. Suzumura, “CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia,” GLIA, vol. 63, no. 12, pp. 2274–2284, 2015. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Ljubisavljevic, I. Stojanovic, S. Vojinovic et al., “The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF,” Neurochemistry International, vol. 62, no. 7, pp. 988–997, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. J.-Z. Guan, W.-P. Guan, T. Maeda, X. Guoqing, W. GuangZhi, and N. Makino, “Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening,” Molecular and Cellular Biochemistry, vol. 400, no. 1-2, pp. 183–187, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Tully, L. Zheng, and R. Shi, “Acrolein detection: potential theranostic utility in multiple sclerosis and spinal cord injury,” Expert Review of Neurotherapeutics, vol. 14, no. 6, pp. 679–685, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. A. P. Kallaur, E. M. V. Reiche, S. R. Oliveira et al., “Genetic, immune-inflammatory, and oxidative stress biomarkers as predictors for disability and disease progression in multiple sclerosis,” Molecular Neurobiology, 2016. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Ivica and J. Wilhelm, “Lipophilic fluorescent products of free radicals,” Biomedical Papers, vol. 158, no. 3, pp. 365–372, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. S. R. Oliveira, A. N. Colado Simão, A. P. Kallaur et al., “Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress,” Nutrition, vol. 30, no. 3, pp. 268–273, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Arnold, R. Bissinger, and F. Lang, “Mitoxantrone-induced suicidal erythrocyte death,” Cellular Physiology and Biochemistry, vol. 34, no. 5, pp. 1756–1767, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Pasquali, C. Pecori, C. Lucchesi et al., “Plasmatic oxidative stress biomarkers in multiple sclerosis: relation with clinical and demographic characteristics,” Clinical Biochemistry, vol. 48, no. 1-2, pp. 19–23, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. R. Shi, T. Rickett, and W. Sun, “Acrolein-mediated injury in nervous system trauma and diseases,” Molecular Nutrition and Food Research, vol. 55, no. 9, pp. 1320–1331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. P. Kharel, J. McDonough, and S. Basu, “Evidence of extensive RNA oxidation in normal appearing cortex of multiple sclerosis brain,” Neurochemistry International, vol. 92, pp. 43–48, 2016. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Morel, M. Bijak, E. Miller, J. Rywaniak, S. Miller, and J. Saluk, “Relationship between the increased haemostatic properties of blood platelets and oxidative stress level in multiple sclerosis patients with the secondary progressive stage,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 240918, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Ljubisavljevic, “Oxidative stress and neurobiology of demyelination,” Molecular Neurobiology, vol. 53, no. 1, pp. 744–758, 2016. View at Publisher · View at Google Scholar · View at Scopus
  92. J. M. Matés, C. Pérez-Gómez, and I. N. De Castro, “Antioxidant enzymes and human diseases,” Clinical Biochemistry, vol. 32, no. 8, pp. 595–603, 1999. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Z. Chae, S. W. Kang, and S. G. Rhee, “Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin,” Methods in Enzymology, vol. 300, pp. 219–226, 1999. View at Publisher · View at Google Scholar · View at Scopus
  94. M. S. E. Aleagha, B. Siroos, M. Ahmadi et al., “Decreased concentration of Klotho in the cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis,” Journal of Neuroimmunology, vol. 281, pp. 5–8, 2015. View at Publisher · View at Google Scholar · View at Scopus
  95. C. Cervellati, A. Romani, E. Fainardi et al., “Serum ferroxidase activity in patients with multiple sclerosis: A Pilot Study,” In Vivo, vol. 28, no. 6, pp. 1197–1200, 2014. View at Google Scholar · View at Scopus
  96. T. Gholipour, T. Ghazizadeh, S. Babapour et al., “Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis,” Iranian Journal of Allergy, Asthma and Immunology, vol. 14, no. 1, pp. 91–97, 2015. View at Google Scholar · View at Scopus
  97. A. Ceriello, N. Bortolotti, E. Falleti et al., “Total radical-trapping antioxidant parameter in NIDDM patients,” Diabetes Care, vol. 20, no. 2, pp. 194–197, 1997. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Gironi, B. Borgiani, E. Mariani et al., “Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment,” Journal of Immunology Research, vol. 2014, Article ID 961863, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. E. Miller, A. Morel, L. Saso, and J. Saluk, “Melatonin redox activity. Its potential clinical applications in neurodegenerative disorders,” Current Topics in Medicinal Chemistry, vol. 15, no. 2, pp. 163–169, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Emamgholipour, A. Hossein-Nezhad, M. A. Sahraian, F. Askarisadr, and M. Ansari, “Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes,” Life Sciences, vol. 145, pp. 34–41, 2016. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Salemme, A. R. Togna, A. Mastrofrancesco et al., “Anti-inflammatory effects and antioxidant activity of dihydroasparagusic acid in lipopolysaccharide-activated microglial cells,” Brain Research Bulletin, vol. 120, pp. 151–158, 2016. View at Publisher · View at Google Scholar · View at Scopus
  102. G. Morris, K. Walder, B. K. Puri, M. Berk, and M. Maes, “The deleterious effects of oxidative and nitrosative stress on palmitoylation, membrane lipid rafts and lipid-based cellular signalling: new drug targets in neuroimmune disorders,” Molecular Neurobiology, vol. 53, no. 7, pp. 4638–4658, 2016. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Khalili, S. Eghtesadi, A. Mirshafiey et al., “Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial,” Nutritional Neuroscience, vol. 17, no. 1, pp. 16–20, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Sanoobar, S. Eghtesadi, A. Azimi, M. Khalili, S. Jazayeri, and M. Reza Gohari, “Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis,” The International Journal of Neuroscience, vol. 123, no. 11, pp. 776–782, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. S. M. Fiebiger, H. Bros, T. Grobosch et al., “The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse,” Journal of Neuroimmunology, vol. 262, no. 1-2, pp. 66–71, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Ghaffari, H. Hatami, and G. Dehghan, “Saffron ethanolic extract attenuates oxidative stress, spatial learning, and memory impairments induced by local injection of ethidium bromide,” Research in Pharmaceutical Sciences, vol. 10, no. 3, pp. 222–232, 2015. View at Google Scholar · View at Scopus
  107. N. A. Noor, H. M. Fahmy, F. F. Mohammed, A. A. Elsayed, and N. M. Radwan, “Nigella sativa amliorates inflammation and demyelination in the experimental autoimmune encephalomyelitis-induced Wistar rats,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 6, pp. 6269–6286, 2015. View at Google Scholar · View at Scopus
  108. W.-Y. Ong, T. Farooqui, G. Kokotos, and A. A. Farooqui, “Syntheti and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders,” ACS Chemical Neuroscience, vol. 6, no. 6, pp. 814–831, 2015. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Naziroglu, S. Kutluhan, I. S. Övey, M. Aykur, and V. A. Yurekli, “Modulation of oxidative stress, apoptosis, and calcium entry in leukocytes of patients with multiple sclerosis by Hypericum perforatum,” Nutritional Neuroscience, vol. 17, no. 5, pp. 214–221, 2014. View at Publisher · View at Google Scholar · View at Scopus
  110. E. Mauriz, A. Laliena, D. Vallejo et al., “Effects of a low-fat diet with antioxidant supplementation on biochemical markers of multiple sclerosis long-term care residents,” Nutricion Hospitalaria, vol. 28, no. 6, pp. 2229–2235, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. V. P. Dadhania, P. P. Trivedi, A. Vikram, and D. N. Tripathi, “Nutraceuticals against neurodegeneration: a mechanistic insight,” Current Neuropharmacology, vol. 14, no. 6, pp. 627–640, 2016. View at Publisher · View at Google Scholar
  112. L. González-González, J. G. Pérez-Cortéz, M. Flores-Aldana, N. Macías-Morales, and C. Hernández-Girón, “Antioxidant use as dietary therapy in patients with multiple sclerosis,” Medwave, vol. 15, no. 1, Article ID e6065, 2015. View at Publisher · View at Google Scholar · View at Scopus
  113. J. J. A. Hendriks, H. E. De Vries, S. M. A. Van Der Pol, T. K. Van Den Berg, E. A. F. Van Tol, and C. D. Dijkstra, “Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study,” Biochemical Pharmacology, vol. 65, no. 5, pp. 877–885, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. K. L. Heckman, W. Decoteau, A. Estevez et al., “Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain,” ACS Nano, vol. 7, no. 12, pp. 10582–10596, 2013. View at Publisher · View at Google Scholar · View at Scopus
  115. B. Li, W. Cui, J. Liu et al., “Sulforaphane ameliorates the development of experimental autoimmune encephalomyelitis by antagonizing oxidative stress and Th17-related inflammation in mice,” Experimental Neurology, vol. 250, pp. 239–249, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. S. Rezapour-Firouzi, S. R. Arefhosseini, M. Ebrahimi-Mamaghani et al., “Activity of liver enzymes in multiple sclerosis patients with Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention,” Complementary Therapies in Medicine, vol. 22, no. 6, pp. 986–993, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. N. Scolding, R. Franklin, S. Stevens, C.-H. Heldin, A. Compston, and J. Newcombe, “Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis,” Brain, vol. 121, no. 12, pp. 2221–2228, 1998. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Bonora, E. De Marchi, S. Patergnani et al., “Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process,” Cell Death and Differentiation, vol. 21, no. 8, pp. 1198–1208, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. T. Kuhlmann, V. Miron, Q. Cuo, C. Wegner, J. Antel, and W. Brück, “Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis,” Brain, vol. 131, no. 7, pp. 1749–1758, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. G. Wolswijk, “Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord,” Brain, vol. 125, no. 2, pp. 338–349, 2002. View at Publisher · View at Google Scholar · View at Scopus
  121. O. Maier, R. Fischer, C. Agresti, and K. Pfizenmaier, “TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress,” Biochemical and Biophysical Research Communications, vol. 440, no. 2, pp. 336–341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. S. EL Andaloussi, S. Lakhal, I. Mäger, and M. J. A. Wood, “Exosomes for targeted siRNA delivery across biological barriers,” Advanced Drug Delivery Reviews, vol. 65, no. 3, pp. 391–397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. A. D. Pusic, K. M. Pusic, B. L. L. Clayton, and R. P. Kraig, “IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination,” Journal of Neuroimmunology, vol. 266, no. 1-2, pp. 12–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. R. Gold, C. Linington, and H. Lassmann, “Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research,” Brain, vol. 129, no. 8, pp. 1953–1971, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. K. J. Smith, R. Kapoor, and P. A. Felts, “Demyelination: the role of reactive oxygen and nitrogen species,” Brain Pathology, vol. 9, no. 1, pp. 69–92, 1999. View at Google Scholar · View at Scopus
  126. G. Leung, W. Sun, L. Zheng, S. Brookes, M. Tully, and R. Shi, “Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune enchephalomyelitis mouse,” Neuroscience, vol. 173, pp. 150–155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. K. Hamann, G. Nehrt, H. Ouyang, B. Duerstock, and R. Shi, “Hydralazine inhibits compression and acrolein-mediated injuries in ex vivo spinal cord,” Journal of Neurochemistry, vol. 104, no. 3, pp. 708–718, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. K. Hamann and R. Shi, “Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury,” Journal of Neurochemistry, vol. 111, no. 6, pp. 1348–1356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. P. K. Kamat, A. Kalani, P. Kyles, S. C. Tyagi, and N. Tyagi, “Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease,” Cell Biochemistry and Biophysics, vol. 70, no. 2, pp. 707–719, 2014. View at Publisher · View at Google Scholar · View at Scopus
  130. A. Abdanipour, T. Tiraihi, A. Noori-Zadeh, A. Majdi, and R. Gosaili, “Evaluation of lovastatin effects on expression of anti-apoptotic Nrf2 and PGC-1α genes in neural stem cells treated with hydrogen peroxide,” Molecular Neurobiology, vol. 49, no. 3, pp. 1364–1372, 2014. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Schachter, “Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update,” Fundamental and Clinical Pharmacology, vol. 19, no. 1, pp. 117–125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  132. C. Hölscher, “Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases,” The Journal of Endocrinology, vol. 221, no. 1, pp. T31–T41, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. C. Hölscher, “Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection,” CNS Drugs, vol. 26, no. 10, pp. 871–882, 2012. View at Publisher · View at Google Scholar · View at Scopus
  134. H. Zhang, A. Ray, N. M. Miller, D. Hartwig, K. A. Pritchard, and B. N. Dittel, “Inhibition of myeloperoxidase at the peak of experimental autoimmune encephalomyelitis restores blood-brain barrier integrity and ameliorates disease severity,” Journal of Neurochemistry, vol. 136, no. 4, pp. 826–836, 2016. View at Publisher · View at Google Scholar · View at Scopus
  135. H.-M. Yun, K.-R. Park, E.-C. Kim, and J. T. Hong, “PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption,” Oncotarget, vol. 6, no. 25, pp. 20875–20884, 2015. View at Publisher · View at Google Scholar · View at Scopus
  136. I. R. Stojanovic, M. Kostic, and S. Ljubisavljevic, “The role of glutamate and its receptors in multiple sclerosis,” Journal of Neural Transmission, vol. 121, no. 8, pp. 945–955, 2014. View at Publisher · View at Google Scholar · View at Scopus
  137. M. T. Viscomi, L. Latini, E. Bisicchia, V. Sasso, and M. Molinari, “Remote degeneration: insights from the hemicerebellectomy model,” Cerebellum, vol. 14, no. 1, pp. 15–18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  138. M. T. Viscomi and M. Molinari, “Remote neurodegeneration: multiple actors for one play,” Molecular Neurobiology, vol. 50, no. 2, pp. 368–389, 2014. View at Publisher · View at Google Scholar · View at Scopus
  139. P. Pacher and K. Mackie, “Interplay of cannabinoid 2 (CB2) receptors with nitric oxide synthases, oxidative and nitrative stress, and cell death during remote neurodegeneration,” Journal of Molecular Medicine, vol. 90, no. 4, pp. 347–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  140. H. Huang, A. Taraboletti, and L. P. Shriver, “Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes,” Redox Biology, vol. 5, pp. 169–175, 2015. View at Publisher · View at Google Scholar · View at Scopus
  141. Q. Wang, S. Chuikov, S. Taitano et al., “Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway,” International Journal of Molecular Sciences, vol. 16, no. 6, pp. 13885–13907, 2015. View at Publisher · View at Google Scholar · View at Scopus
  142. S. Licht-Mayer, I. Wimmer, S. Traffehn et al., “Cell type-specific Nrf2 expression in multiple sclerosis lesions,” Acta Neuropathologica, vol. 130, no. 2, pp. 263–277, 2015. View at Publisher · View at Google Scholar · View at Scopus
  143. T. Dehmel, M. Döbert, S. Pankratz et al., “Monomethylfumarate reduces in vitro migration of mononuclear cells,” Neurological Sciences, vol. 35, no. 7, pp. 1121–1125, 2014. View at Publisher · View at Google Scholar · View at Scopus
  144. I. Lastres-Becker, A. J. García-Yagüe, R. H. Scannevin et al., “Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease,” Antioxidants & Redox Signaling, vol. 25, no. 2, pp. 61–77, 2016. View at Publisher · View at Google Scholar
  145. S. E. Fiedler, A. R. Kerns, C. Tsang, V. Tsang, D. Bourdette, and S. Salinthone, “Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells,” Biochemical and Biophysical Research Communications, vol. 475, no. 1, pp. 19–24, 2016. View at Publisher · View at Google Scholar
  146. T. Kume, A. Suenaga, Y. Izumi, and A. Akaike, “Protective effect of dimethyl fumarate on an oxidative stress model induced by sodium nitroprusside in mice,” Biological & Pharmaceutical Bulletin, vol. 39, no. 6, pp. 1055–1059, 2016. View at Publisher · View at Google Scholar
  147. Y. Liu, J. Qiu, Z. Wang et al., “Dimethylfumarate alleviates early brain injury and secondary cognitive deficits after experimental subarachnoid hemorrhage via activation of Keap1-Nrf2-ARE system,” Journal of Neurosurgery, vol. 123, no. 4, pp. 915–923, 2015. View at Publisher · View at Google Scholar · View at Scopus
  148. R. Kunze, A. Urrutia, A. Hoffmann et al., “Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity,” Experimental Neurology, vol. 266, pp. 99–111, 2015. View at Publisher · View at Google Scholar · View at Scopus
  149. C. To, C. S. Ringelberg, D. B. Royce et al., “Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis,” Carcinogenesis, vol. 36, no. 7, pp. 769–781, 2015. View at Publisher · View at Google Scholar · View at Scopus
  150. C. Schuh, I. Wimmer, S. Hametner et al., “Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models,” Acta Neuropathologica, vol. 128, no. 2, pp. 247–266, 2014. View at Publisher · View at Google Scholar · View at Scopus
  151. M. Serdar, J. Herz, K. Kempe et al., “Fingolimod protects against neonatal white matter damage and long-term cognitive deficits caused by hyperoxia,” Brain, Behavior, and Immunity, vol. 52, pp. 106–119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  152. A. D. Pusic and R. P. Kraig, “Phasic treatment with interferon gamma stimulates release of exosomes that protect against spreading depression,” Journal of Interferon and Cytokine Research, vol. 35, no. 10, pp. 795–807, 2015. View at Publisher · View at Google Scholar · View at Scopus
  153. H. M. Schipper, D. Arnold, F. Grand'Maison et al., “Tolerability and safety of combined glatiramer acetate and N-acetylcysteine in relapsing-remitting multiple sclerosis,” Clinical Neuropharmacology, vol. 38, no. 4, pp. 127–131, 2015. View at Publisher · View at Google Scholar · View at Scopus
  154. C. G. Pascuan, E. H. Simon, A. M. Genaro, and M. L. Palumbo, “Involvement of nitric oxide in improving stress-induced behavioural alteration by glatiramer acetate treatment in female BALB/c mice,” Psychopharmacology, vol. 232, no. 9, pp. 1595–1605, 2015. View at Publisher · View at Google Scholar · View at Scopus
  155. M. Adamczyk-Sowa, K. Pierzchala, P. Sowa, R. Polaniak, M. Kukla, and M. Hartel, “Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients,” Journal of Physiology and Pharmacology, vol. 65, no. 4, pp. 543–550, 2014. View at Google Scholar · View at Scopus
  156. M. Adamczyk-Sowa, K. Pierzchala, P. Sowa et al., “Melatonin acts as antioxidant and improves sleep in MS patients,” Neurochemical Research, vol. 39, no. 8, pp. 1585–1593, 2014. View at Publisher · View at Google Scholar · View at Scopus
  157. G. Pentón-Rol, N. Lagumersindez-Denis, L. Muzio et al., “Comparative neuroregenerative effects of C-phycocyanin and IFN-beta in a model of multiple sclerosis in mice,” Journal of Neuroimmune Pharmacology, vol. 11, no. 1, pp. 153–167, 2016. View at Publisher · View at Google Scholar · View at Scopus
  158. C. Bahamonde, C. Conde, E. Agüera et al., “Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress,” European Journal of Pharmacology, vol. 730, no. 1, pp. 26–30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  159. I. Tasset, E. Agüera, F. Gascón et al., “Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis,” Revista de Neurologia, vol. 54, no. 8, pp. 449–452, 2012. View at Google Scholar · View at Scopus
  160. A. Jamroz-Wisniewska, J. Beltowski, Z. Stelmasiak, and H. Bartosik-Psujek, “Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy,” Acta Neurologica Scandinavica, vol. 127, no. 6, pp. e33–e36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  161. F. Molinari, V. Simonetti, M. Franzini et al., “Ozone autohemotherapy induces long-term cerebral metabolic changes in multiple sclerosis patients,” International Journal of Immunopathology and Pharmacology, vol. 27, no. 3, pp. 379–389, 2014. View at Google Scholar · View at Scopus
  162. N. A. Salem, N. Assaf, M. F. Ismail, Y. A. Khadrawy, and M. Samy, “Ozone therapy in ethidium bromide-induced demyelination in rats: possible protective effect,” Cellular and Molecular Neurobiology, vol. 36, no. 6, pp. 943–954, 2016. View at Publisher · View at Google Scholar · View at Scopus